Pravastatin promotes coronary collateral circulation in patients with coronary artery disease
- 1 November 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 13 (7) , 377-381
- https://doi.org/10.1097/00019501-200211000-00005
Abstract
Previous studies suggested that hydroxymethylglutaryl coenzyme A reductase inhibitor (statin) promotes collateral circulation in ischemic limbs of rabbits. The present study was designed to determine the association between treatment with pravastatin and the development of coronary collateral circulation as assessed by the Rentrop Score in patients with coronary artery disease (CAD) in a case–control study. The study included patients who had one (1-V), two (2-V) or three (3-V) significantly stenosed vessels. Patients who did and did not receive pravastatin were defined as case participants (n = 42) and control participants (n = 100), respectively. The case participants included a higher percentage of 3-V patients with a Rentrop Score 1 compared to the control participants but there was no difference among 1-V and 2-V patients, suggesting that pravastatin was associated with coronary collateral circulation independent of the number of stenosed vessels. Patients with 3-V disease who were treated with pravastatin were most likely [odds ratio (confidence interval), 17.4 (4.4–115)] to develop collateral circulation, as assessed by multiple logistic regression analysis. Treatment with pravastatin was associated with the development of collateral circulation in patients with CAD, suggesting that such action constitutes part of the pleiotropic effects of statin.Keywords
This publication has 28 references indexed in Scilit:
- Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary InterventionCirculation, 2002
- Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase InhibitorsArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- HMG-CoA reductase inhibitor mobilizes bone marrow–derived endothelial progenitor cellsJournal of Clinical Investigation, 2001
- HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathwayJournal of Clinical Investigation, 2001
- Early Statin Treatment Following Acute Myocardial Infarction and 1-Year SurvivalJAMA, 2001
- The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.Nature Medicine, 2000
- Cholesterol Reduction Rapidly Improves Endothelial Function After Acute Coronary SyndromesCirculation, 1999
- The future of best practiceAtherosclerosis, 1999
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995